Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC

Inclusion Criteria: * Patients must have pathologically confirmed non-small cell lung cancer, of either squamous or non-squamous histology. * Stage 1B-3A * Deemed surgically resectable by a thoracic surgeon * Age ≥ 18 years * Radiologically measurable disease, as defined by response evaluation criteria in solid tumours (RECIST) v1.1 * Ability to understand and the willingness to sign a written informed consent document * Females of child-bearing potential must: * Either commit to true abstinence from heterosexual contact, or agree to use, and be able to comply with, effective contraception (\</=1% failure rate annually) without interruption, 28 days prior to starting therapy (including dose interruptions), and while on study medication or for a period of 90 days following treatment completion. * Have a negative serum pregnancy test (β -hCG) result at screening and agree to ongoing pregnancy testing during the course of the study, and after the end of study therapy. * Male subjects must practice true abstinence or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for 6 months following treatment discontinuation, even if he has undergone a successful vasectomy. * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 * Representative formalin-fixed paraffin-embedded (FFPE) tumor specimens in paraffin blocks (blocks are preferred) or at lea…